

NHS Foundation Trust

Ref: 02869_04015_2018-04-25_01

Date: 25 April 2018

Standing Way
Eaglestone
Milton Keynes
MK6 5LD
Tel: 01908 660033
www.mkhospital.nhs.uk
For people who have hearing loss
Minicom 01908 243924

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on 12 April 2018.

I am pleased to confirm the following.

	Total number treated Stage IIIB/IV NSCLC Patients	If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:
Patients with NSCLC Stage IIIB/IV (Stage 3b/4) ¹	24	Total number NSCLC patients Other (please specify)
		Data not held/accessible

Of the Stage IIIB/IV NSCLC patients, please indicate the number of patients treated by your Trust in the 3 months December 2017 to February 2018 inclusive, with the following therapies.

Docetaxel (mono or combination therapy) Total number NSCLC patients Other (please specify) Data not held/accessible Atezolizumab (Tecentriq) Other (please specify) Data not held/accessible Nivolumab (Opdivo) Other (please specify) Data not held/accessible Other (please specify) Data not held/accessible Other (please specify) Data not held/accessible Total number NSCLC patients Other (please specify) Data not held/accessible		Total number treated Stage IIIB/IV NSCLC Patients	If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:	
Atezolizumab (Tecentriq) Other (please specify) Data not held/accessible Total number NSCLC patients Other (please specify) Data not held/accessible Nivolumab (Opdivo) Other (please specify) Total number NSCLC patients Other (please specify) Data not held/accessible	,	1	Total number NSCLC patients	
Atezolizumab (Tecentriq) Other (please specify) Data not held/accessible Nivolumab (Opdivo) Other (please specify) Total number NSCLC patients Other (please specify) Data not held/accessible			Other (please specify)	
Other (please specify) Data not held/accessible Nivolumab (Opdivo) Other (please specify) Total number NSCLC patients Other (please specify) Data not held/accessible			Data not held/accessible	
Data not held/accessible Nivolumab (Opdivo) Other (please specify) Data not held/accessible	Atezolizumab (Tecentriq)	0	Total number NSCLC patients	
Nivolumab (Opdivo) 0 Total number NSCLC patients Other (please specify) Data not held/accessible			Other (please specify)	
Other (please specify) Data not held/accessible			Data not held/accessible	
Data not held/accessible	Nivolumab (Opdivo)	0	Total number NSCLC patients	
			Other (please specify)	
Pembrolizumah (Keytruda) 6 Total number NSCLC patients			Data not held/accessible	
Tembronzumab (Reytrada)	Pembrolizumab (Keytruda)	6	Total number NSCLC patients	



Other (please specify)	
Data not held/accessible	

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom Of Information Co-ordinator For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.